Status:

COMPLETED

Dexmedetomidine and Neuroprotection in Children Undergoing General Anesthesia

Lead Sponsor:

Seoul National University Hospital

Conditions:

Dexmedetomidine

Eligibility:

All Genders

1-3 years

Phase:

NA

Brief Summary

Neuroapoptosis is induced by the administration of anesthetic agents to the young brain. Recent studies showed that the a2-adrenoceptor agonist, dexmedetomidine plays a trophic role during development...

Detailed Description

GFAP measure

Eligibility Criteria

Inclusion

  • children undergoing general anesthesia longer than 3 hours

Exclusion

  • past history of anesthesia
  • cardiopulmonary bypass
  • preexisting neurocognitive dysfunction
  • abnormalities of liver profile (aspartate transaminase \> 40 unit/L, alanine aminotransferase \> 40 unit/L)

Key Trial Info

Start Date :

September 1 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 5 2019

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT03234660

Start Date

September 1 2017

End Date

October 5 2019

Last Update

January 2 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

SNUH

Seoul, Jongro Gu, South Korea, 15710

Dexmedetomidine and Neuroprotection in Children Undergoing General Anesthesia | DecenTrialz